OrthoPediatrics

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OrthoPediatrics achieves record revenue growth and eyes international expansion

OrthoPediatrics delivered strong financial performance in 2022, achieving profitability and record revenue growth despite challenges. With a focus on new product launches, international expansion, and surgeon training, the company is well-positioned for continued growth and profitability.

OrthoPediatrics reports robust Q1 earnings, eyes international growth opportunities

OrthoPediatrics had a strong Q1 2023, with increased revenue guidance for the full year. The company remains cautiously optimistic due to staffing dynamics. Focus on new product development, acquisitions, and addressing digital needs of children's hospitals highlight growth strategies.

OrthoPediatrics achieves record Q2 performance amidst growth challenges

OrthoPediatrics delivered strong Q2 results with record child assistance and revenue growth, driven by trauma, deformity, and international segments.
While facing challenges like atypical growth patterns and delays in product launches, the company is well-positioned to capitalize on opportunities in enabling technologies and international expansion.
The focus on long-term growth drivers and strategic acquisitions underscores OrthoPediatrics' commitment to sustainable growth and innovation in pediatric orthopedics.
Overall, OrthoPediatrics' performance highlights operational efficiency, market demand, and a clear path for future growth and expansion.

OrthoPediatrics achieves record revenue in Q3 2023, eyes continued growth

OrthoPediatrics reported strong financial performance in Q3 2023, with record revenue and EBITDA, positioning the company for future growth. Despite challenges in certain segments, opportunities in new product launches, international expansion, and surgeon training initiatives offer avenues for continued success. The company's positive outlook and robust pipeline indicate a promising trajectory for OrthoPediatrics.

OrthoPediatrics achieves record revenue and EBITDA, eyes international expansion

OrthoPediatrics delivered strong financial performance in 2023, setting revenue and EBITDA records. The company's strategic focus on sustainable growth, profitability, and diversification positions it well for future success.

OrthoPediatrics reports robust Q1 growth, raises full-year revenue guidance

OrthoPediatrics demonstrated strong performance in Q1 2024 with significant growth in patients helped, revenue, and key business segments. While facing challenges such as an EBITDA loss and increased expenses, the company's focus on growth, new product launches, and financial targets positions it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WARSAW, Ind., Dec.  20, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the U.S. launch of QuickPack™, a fully synthetic bone graft substitute featuring a high viscosity, calcium phosphate cement that closely mimics the mineral phase of natural bone.

OrthoPediatrics Corp. Announces U.S. Launch of QuickPack™

WARSAW, Ind., Dec.  17, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today the closing of its underwritten follow-on public offering of 1,805,500 shares of its common stock at a price to the public of $36.50 per share, which included the exercise in full by the underwriters of their option to purchase additional shares of common stock on the same terms and conditions. 1,755,500 of the shares were offered by OrthoPediatrics and 50,000 shares were offered by certain selling stockholders. Gross proceeds to OrthoPediatrics were approximately $64.1 million, before deducting underwriting discounts and commissions and offering expenses payable by OrthoPediatrics.

OrthoPediatrics Corp. Announces Closing of Common Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

WARSAW, Ind., Dec.  11, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today the pricing of its underwritten public offering of 1,570,000 shares of its common stock at a price to the public of $36.50 per share. 1,520,000 of the shares are being offered by OrthoPediatrics and 50,000 shares are being offered by certain selling stockholders. OrthoPediatrics will not receive any proceeds from the sale of the shares by the selling stockholders.

OrthoPediatrics Corp. - Announces Pricing of Offering of Common Stock

WARSAW, Ind., Dec.  10, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (Nasdaq: KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, announced today that it is commencing an underwritten public offering of its common stock. OrthoPediatrics and certain of its stockholders are proposing to sell shares of common stock, including shares to be offered by certain selling stockholders. OrthoPediatrics will not receive any proceeds from the sale of the shares by the selling stockholders. In addition, OrthoPediatrics intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

OrthoPediatrics Corp. - Announces Proposed Public Offering of Common Stock

WARSAW, Ind., Nov.  15, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, is pleased to announce the domestic launch of the PediFoot Deformity Correction System (“PediFoot”), following 510(k) clearance by the U.S. Food and Drug Administration (FDA) in August.

OrthoPediatrics Corp. Announces U.S. Launch of PediFoot Deformity Correction System.

OrthoPediatrics Corp.'s (KIDS) CEO Mark Throdahl on Q3 2019 Results - Earnings Call Transcript

WARSAW, Ind., Sept.  25, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ:KIDS), an orthopedic company focused exclusively on advancing the field of pediatric orthopedics, announced today that Mark Throdahl, President & Chief Executive Officer, and Dave Bailey, Executive Vice President, are scheduled to participate at the Cantor Fitzgerald Global Healthcare Conference being held October 2-4, 2019 in New York, NY.

OrthoPediatrics Corp. to Participate at the Cantor Fitzgerald Global Healthcare Conference

WARSAW, Ind., Sept.  16, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today it will continue its support as a Platinum Level Sponsor for the 73rd Annual Meeting of the American Academy for Cerebral Palsy and Developmental Medicine (“AACPDM”), which will take place September 18-21 in Anaheim, California. The Company will also sponsor the 2019 Scoliosis Research Society (“SRS”) 54th Annual Meeting & Course as a Gold Level Sponsor, which will take place September 18-21 in Montreal, Canada. Additionally, the Company will attend the Orthopedic Trauma Association (“OTA”) 35th Annual Meeting, which will take place September 25-28 in Denver, Colorado.

OrthoPediatrics Corp. to Sponsor Three Medical Meetings in September 2019

WARSAW, Ind., Aug.  19, 2019  (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced today it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new PediFoot Deformity Correction System (“PediFoot”), the first pediatric-specific system to treat fractures and deformities of the foot and ankle. 

OrthoPediatrics Corp. Receives FDA 510(k) Clearance for First Pediatric-Specific Foot System

OrthoPediatrics Corp (KIDS) CEO Mark Throdahl on Q2 2019 Results - Earnings Call Transcript

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -55.56% and -0.73%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Reports Q2 Loss, Lags Revenue Estimates

OrthoPediatrics Corp. (KIDS) CEO Mark Throdahl on Q1 2019 Results - Earnings Call Transcript

KIDS earnings call for the period ending December 31, 2018.

News for OrthoPediatrics Stock (KIDS)